Evidence map›Paper›PMID 36536103›Full record

ArticleNature structural & molecular biology2023

A pioneer factor locally opens compacted chromatin to enable targeted ATP-dependent nucleosome remodeling.

Megan A Frederick, Kaylyn E Williamson, Meilin Fernandez Garcia, Max B Ferretti, Ryan L McCarthy, Greg Donahue, Edgar Luzete Monteiro, Naomi Takenaka, Janice Reynaga, Cigall Kadoch and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. PervasivebioRxiv : the preprint server for biology · 2025
    Article
  13. Article
  14. Circadian regulator REV-ERBα is a master regulator of tumor lineage plasticity and an effective therapeutic target.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Megan A FrederickInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3808-8744
Kaylyn E WilliamsonDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3252-5050
Meilin Fernandez GarciaInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Max B FerrettiDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-2961-6362
Ryan L McCarthyInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Greg DonahueInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Edgar Luzete MonteiroInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Naomi TakenakaInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Janice ReynagaInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Cigall KadochDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4058-5985
Kenneth S ZaretInstitute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. zaret@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0001-8932-3145
California Institute for Regenerative Medicine · USHarvard University · USPenn Center for AIDS Research · USUniversity of Pennsylvania · US

Funding

TRANS-ACTING FACTORS CAUSING CELL-SPECIFIC GENE CONTROLR01GM036477 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ZARET, KENNETH · 1986 to 2023
$7.7M
HEMATOPOIESIS TRAINING GRANTT32DK007780 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI TONG, WEI · 1999 to 2023
$6.7M
Trans-acting Factors Causing Cell Specific Gene ControlR37GM036477 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ZARET, KENNETH · 2006 to 2015
$5.4M
Assessing the basis of chromatin opening by hematopoietic pioneer factorsF31DK123886 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FREDERICK, MEGAN A. · 2019 to 2022
$125k
NIDDK NIH HHS F31 DK123886NIDDK NIH HHS T32 DK007780NIGMS NIH HHS R01 GM036477NIGMS NIH HHS R37 GM036477
6 · The paper itself

Abstract

To determine how different pioneer transcription factors form a targeted, accessible nucleosome within compacted chromatin and collaborate with an ATP-dependent chromatin remodeler, we generated nucleosome arrays in vitro with a central nucleosome containing binding sites for the hematopoietic E-Twenty Six (ETS) factor PU.1 and Basic Leucine Zipper (bZIP) factors C/EBPα and C/EBPβ. Our long-read sequencing reveals that each factor can expose a targeted nucleosome on linker histone-compacted arrays, but with different nuclease sensitivity patterns. The DNA binding domain of PU.1 binds mononucleosomes, but requires an additional intrinsically disordered domain to bind and open compacted chromatin. The canonical mammalian SWI/SNF (cBAF) remodeler was unable to act upon two forms of locally open chromatin unless cBAF was enabled by a separate transactivation domain of PU.1. cBAF potentiates the PU.1 DNA binding domain to weakly open chromatin in the absence of the PU.1 disordered domain. Our findings reveal a hierarchy by which chromatin is opened and show that pioneer factors can provide specificity for action by nucleosome remodelers.

Indexed as

ChromatinNucleosomesAdenosine TriphosphateAnimalsChromatin Assembly and DisassemblyDNAMammalsTranscription FactorsAdenosine TriphosphateChromatinDNANucleosomesTranscription Factors

Identifiers

PMID36536103
PMCPMC10004348
OpenAlexW4312018895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.